Abbott Laboratories Corporation

Dade International Inc.

Baxter Diagnostics Inc.

Dinesh O Shah

Suresh M Desai

George J Dawson

Thomas P Leary

Joan D Tyner

David J Hawksworth

Robert N Ziemann

Susan E Brophy

Bryan C Tieman

Bailin Tu

A Scott Muerhoff

Robert William Siegel

Robin A Gutierrez

James L Stewart

Chao-Huei J Wang

Lily Jiang

Michael E Jolley

Anthony Scott Muerhoff

Larry G Birkenmeyer

Kurt M Klosterman

Kevin Y Cheng

Terukatsu Arima

Chi-Deu Chang

John A Todd

Russell B Richerson

Delia R Bethell

David C Leahy

Tarun Chandra

Xingli Jiang

Chaeo-Huej J Wang

James P Mackowiak

Natalie Dubovoy

Robin A Guetierrez

Gerald Schochetman

Yu Cheng

Joan D(deceased) Tyner

George A Dawson

The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of

[object Object]

A polypeptide comprising the contiguous amino acids 1-198 of SEQ ID NO: 2; a polypeptide, which comprises a contiguous amino acid sequence that is at least about 95% identical to the contiguous amino acids 1-198 of SEQ ID NO: 2, an epitope that is immunoreactive with an antibody that specifically binds to the core protein of hepatitis C virus (HCV), and an epitope that is immunoreactive with an antibody that specifically binds to the NS4 region of HCV; a nucleic acid encoding such a polypeptide; a host cell comprising such a nucleic acid; an immunodiagnostic reagent comprising such a polypeptide; a kit comprising such an immunodiagnostic reagent; and a method of determining the presence, amount, or concentration of anti-HCV antibodies in a test sample.

Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies

The present invention relates to one or more peptides which may be used to test for the presence of antibodies to. These peptide are selected based on the strength and specificity of the human antibody response to. These peptides alone or in combination have a variety of uses, for example, as a component of a diagnostic assay or kit.

The present invention relates to the diagnosis ofinfection.

The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (HCV) antigens as well as antibodies produced in response to HCV antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply.

Methods for the simultaneous detection of HCV antigens and HCV antibodies

The subject invention relates generally to immunoassays for detection of antibodies by use chemiluminescent compounds. More particularly, the subject invention relates to chemiluminescent immunoassays to detect antibodies wherein a precomplex mixture is created and a two-step assay is performed resulting in a greater signal.

Chemiluminescent immunoassay for detection of antibodies to various viruses

This invention provides a novel process of using magnetically responsive fluorescent polymer particles comprising polymeric core particles coated evenly with a layer of polymer containing magnetically responsive metal oxide as highly sensitive quantitative reagents for biochemical and immunological studies, wherein the fluorescent magnetic particles can serve as a marker for the number of particles. A wide variety of polymeric particles with sizes ranging from 1 to 100 microns can be used a core particles and transformed into magnetically responsive polymer particles. The surface of these magnetically responsive polymer particles can be coated further with another layer of functionalized polymer. These magnetically responsive fluorescent polymer particles can be used for passive or covalent coupling of biological material such as antigens, antibodies, enzymes or DNA/RNA hybridization and used as solid phase for various types of immunoassays, DNA/RNA hybridization probes assays, affinity purification, cell separation and other medical, diagnostic, and industrial applications.

Method to use fluorescent magnetic polymer particles as markers in an

A chemiluminescent assay utilizing a precomplex reagent of a probe comprising an enhancer compound such as a hapten and a conjugate comprising a chemiluminescent signal generating compound. Kits for performing such an chemiluminescent assay are also provided.

Chemiluminescent immunoassay for antibody detection

New assays for diagnosing NANBH utilizing novel peptide fragments derived from polypeptide antigens reactive to antibodies present in the sera of infected patients are disclosed. In producing these peptides, the portion of the polypeptide contributing to high backgrounds is deleted thereby resulting in assays with an exceptionally high signal to background ratio.

Assay for Non-A Non-B hepatitis

Embodiments of the invention provide methods of preparing an activated acridinium microparticle. Generally, the methods involve direct covalent coupling or an affinity format. The direct covalent coupling method involves coating a microparticle with a proteinaceous compound. Then, a 10-methyl-N-tosyl-N-(2-carboxyethyl)-9-acridinium carboximide trifluoromethane sulfonate is coupled to the proteinaceous compound. In the affinity format, a microparticle is coated with a biotinylated proteinaceous compound. The microparticle is reacted with an anti-biotin labelled 10-methyl-N-tosyl-N-(2-carboxyethyl)-9-acridinium carboximide trifluoromethane sulfonate. Methods are also provided for using such a microparticle. Those methods of use can estimate transfer efficiency, calibrate optics, and measure membrane pore size of a chemiluminescence based instrument. Test elements for analytical instruments are also provided.

Process for labeling acridinium to microparticles and application in an

This invention provides a novel process of producing magnetically responsive fluorescent polymer particles comprising polymeric core particles coated evenly with a layer of polymer containing magnetically responsive metal oxide. A wide variety of polymeric particles with sizes ranging from 1 to 100 microns can be used a core particles and transformed into magnetically responsive polymer particles. The surface of these magnetically responsive polymer particles can be coated further with another layer of functionalized polymer. These magnetically responsive fluorescent polymer particles can be used for passive or covalent coupling of biological material such as antigens, antibodies, enzymes or DNA/RNA hybridization and used as solid phase for various types of immunoassays, DNA/RNA hybridization probes assays, affinity purification, cell separation and other medical, diagnostic, and industrial applications.

Process to make magnetically responsive fluorescent polymer particles

Growing community of inventors

Libertyville, IL, United States of America

Dinesh O Shah